Depression as the Primary Cause of Insomnia and Excessive Daytime Sleepiness in a Family with Multiple Cases of Spinocerebellar Ataxia

J Clin Sleep Med. 2016 Jul 15;12(7):1059-61. doi: 10.5664/jcsm.5950.

Abstract

Spinocerebellar ataxia (SCA) is a hereditary disease characterized by central nervous system-related motor dysfunctions. Sleep disorders and frequent non-motor manifestations are commonly comorbid with SCA. To elucidate this relationship, we present three cases in a family that included multiple SCA type 2 patients with various sleep disorders. Complete physical examination, and genetic and imaging studies were performed. Anti-parkinsonism medications were prescribed after neurological examination. Clonazepam and/or quetiapine were administered for sleep disorders but failed to resolve insomnia and excessive daytime sleepiness (EDS). Based on DSM-5 criteria, all cases were diagnosed with depression. After treatment with serotonin-norepinephrine reuptake inhibitors and noradrenergic and specific serotonergic antidepressants, symptoms of insomnia and EDS, which are strongly associated with depression in SCA type 2 patients, improved significantly. It is crucial to recognize insomnia and EDS in neurodegenerative diseases, not only for earlier diagnosis, but also to improve quality of life.

Keywords: depression; excessive daytime sleepiness; insomnia; sleep disorders; spinocerebellar ataxia.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antidepressive Agents / therapeutic use
  • Antipsychotic Agents / therapeutic use
  • Clonazepam / therapeutic use
  • Depressive Disorder / complications*
  • Depressive Disorder / drug therapy
  • Disorders of Excessive Somnolence / complications*
  • Disorders of Excessive Somnolence / drug therapy
  • Family
  • Female
  • GABA Modulators / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Quetiapine Fumarate / therapeutic use
  • Selective Serotonin Reuptake Inhibitors / therapeutic use
  • Sleep Initiation and Maintenance Disorders / complications*
  • Sleep Initiation and Maintenance Disorders / drug therapy
  • Spinocerebellar Ataxias / complications*
  • Treatment Outcome

Substances

  • Antidepressive Agents
  • Antipsychotic Agents
  • GABA Modulators
  • Serotonin Uptake Inhibitors
  • Quetiapine Fumarate
  • Clonazepam